Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | Q9HBH1 | 7/20 | 0.61 | |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | MMP3 | P08254 | 3/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497562 | 1.00 | PDF (0.61) | PDFMMP2MMP3MMP1MMP7 | |
| SCHEMBL6760341 | 0.90 | PDF (0.61) | ||
| SCHEMBL14282122 | 0.88 | PDF (0.60) | PDFMMP2MMP3MMP1MMP7 | |
| SCHEMBL6135916 | 0.88 | PDF (0.63) | ||
| SCHEMBL4956865 | 0.87 | PDF (0.80) | ||
| SCHEMBL13754309 | 0.87 | PDF (0.80) | ||
| SCHEMBL4956863 | 0.87 | PDF (0.80) | ||
| SCHEMBL13761273 | 0.87 | PDF (0.80) | ||
| SCHEMBL4956500 | 0.87 | PDF (0.80) | ||
| SCHEMBL7119171 | 0.85 | PDF (0.57) |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054861-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-29 | — | — | EP | claimed |
| WO-1999041232-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-19 | — | — | WO | claimed |
| US-7323448-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323448-B2 | Antibacterial agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20070129310-A1 | Antibacterial agents | VERNALIS (OXFORD) LTD. (GB) | 2007-06-07 | — | — | US | disclosed |
| US-20070129310-A1 | Antibacterial agents | VERNALIS (OXFORD) LTD. (GB) | 2007-06-07 | — | — | US | disclosed |
| US-20070129310-A1 | Antibacterial agents | VERNALIS (OXFORD) LTD. (GB) | 2007-06-07 | — | — | US | disclosed |
| EP-1146868-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000043001-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129310-A1 | Antibacterial agents | ARG1, SCO2, SPOUT1 | PDF 996/4885MMP2 3159/4885MMP3 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.